Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
about
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationAlternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationDifferent doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationWhy has demand for platelet components increased? A reviewAlternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remissionAdvances in haematological pharmacotherapy in 21st century.T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignanciesComparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemiaImpact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemiaCellular therapies in acute lymphoblastic leukemiaAllogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.Alemtuzumab in allogeneic hematopoetic stem cell transplantation.Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.Redefining transplant in acute leukemia.The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission.
P2860
Q24186359-63F9D39A-7493-47AC-8580-5B54EDA176E3Q24186913-F464FFB4-CA59-4B4E-9D9D-1BFAB78DAD28Q24187751-AB4E6405-2171-458E-B117-076E44F082E7Q24198288-11DBD25B-6A85-47B9-81B0-196A4A3F6617Q24198774-2E46FFB9-3C1F-4A95-86FD-B7ED35D604AEQ24198795-C0E82D52-B7E3-48C4-AFE9-FD112868933FQ24198832-BB7CADF1-1D9D-4AF0-B56E-058E1126F6DFQ28249969-9F9B30FB-3BAC-49CA-83F8-B6E4BB3E91B8Q30248355-F1DECBF8-00C6-4C88-855E-3AEF8947F383Q34033852-7C47941D-5E7D-4564-99C5-48D446C98A9BQ34406838-12EBECBE-E436-46D5-93CC-3131BD3AADB4Q34981585-7381123F-F6DE-4F16-A2DA-2584F618C91BQ35243578-05E0D332-D077-487E-92F6-6DB59B2624FDQ35321329-07CDBD3D-C364-498B-858F-0ADC15517695Q36057916-AFD266BC-D260-409D-BAC3-3D8C1AA7E111Q36552098-30D20399-DEB9-4EFD-ABB0-5BFB7202761DQ38226100-9B2CBD29-9979-4730-B3E6-C5191814CC90Q39459351-EC23CE61-527F-420E-BC13-430F7CFA01BFQ42149544-860A6754-D122-4995-9A0F-2FA1A8914F1BQ44399798-FD370183-78A1-4B74-925E-615E6C5C91F8Q44657508-775F8E4E-0261-46F8-AC45-303E327D6B15Q46639944-D258A77F-59AF-48EE-A4E6-B0F75257E071
P2860
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Favorable outcomes with alemtu ...... ia in first complete remission
@en
Favorable outcomes with alemtu ...... a in first complete remission.
@nl
type
label
Favorable outcomes with alemtu ...... ia in first complete remission
@en
Favorable outcomes with alemtu ...... a in first complete remission.
@nl
prefLabel
Favorable outcomes with alemtu ...... ia in first complete remission
@en
Favorable outcomes with alemtu ...... a in first complete remission.
@nl
P2093
P2860
P1433
P1476
Favorable outcomes with alemtu ...... ia in first complete remission
@en
P2093
Adele K Fielding
Anthony H Goldstone
Bella Patel
Bronwen E Shaw
David I Marks
Eduardo Olavarria
Effie Liakopoulou
Gordon Cook
Keiren E Kirkland
Mike N Potter
P2860
P304
P356
10.3324/HAEMATOL.2009.008649
P577
2009-07-31T00:00:00Z